Amgen v. Sanofi: The Supreme Court Takes up the Enablement Requirement in the Context of Therapeutic Monoclonal Antibodies

Abstract

Biotechnology Law ReportVol. 41, No. 6 The Holman ReportAmgen v. Sanofi: The Supreme Court Takes up the Enablement Requirement in the Context of Therapeutic Monoclonal AntibodiesBy Christopher M. HolmanBy Christopher M. HolmanChristopher M. Holman is a Professor of Law at the University of Missouri–Kansas City School of Law; a Senior Scholar at the Center for the Protection of Intellectual Property at the Antonin Scalia Law School, George Mason University; and the Executive Editor of Biotechnology Law Report.Search for more papers by this authorPublished Online:15 Dec 2022https://doi.org/10.1089/blr.2022.29293.cmhAboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 41Issue 6Dec 2022 InformationCopyright 2022, Mary Ann Liebert, Inc., publishersTo cite this article:By Christopher M. Holman.Amgen v. Sanofi: The Supreme Court Takes up the Enablement Requirement in the Context of Therapeutic Monoclonal Antibodies.Biotechnology Law Report.Dec 2022.269-282.http://doi.org/10.1089/blr.2022.29293.cmhPublished in Volume: 41 Issue 6: December 15, 2022Online Ahead of Print:December 7, 2022PDF download